Stoke Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Stoke Therapeutics

13/05/2025 13:20

Stoke Therapeutics Inc STOK.OQ reported quarterly adjusted earnings of $1.98​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -57 cents.  The mean expectation of ten analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -57 cents to -21 cents per share.

Revenue rose 3,661.1% to $158.57 million from a year ago; analysts expected $9.59 million.

Stoke Therapeutics Inc's reported EPS for the quarter was $1.90​.

The company reported quarterly net income of $112.88 million.

Stoke Therapeutics Inc shares had risen by 45.3% this quarter and lost 12.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 31.7% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $22.00

This summary was machine generated from LSEG data May 13 at 12:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.40
1.98
Beat
Dec. 31 2024
-0.53
-0.18
Beat
Sep. 30 2024
-0.53
-0.47
Beat
Jun. 30 2024
-0.56
-0.46
Beat